Halberd Corp (OTCMKTS:HALB) on August 23, 2021, announced filing U.S joint provisional patent application, “Treating Alzheimer’s Disease Utilizing Extracorporeal Radio Frequency.”
As a result of its Sponsored Research conducted at Arizona State University as well as Youngstown State University, the patent application covers technology developed for treating blood or cerebral spinal fluid.
Dr. Mitchell S. Felder, Halberd Corporation’s Chief Technical Officer and co-inventor of the technology said that conjugation of metallic nanoparticles with antibody aims at curing Alzheimer’s Disease-related antigens.
Felder added that the particles stick to antigens and the bodily fluid is exposed to tuned radio frequency waves. The CTO added the removing target antigens slow disease progression and the company is excited about the promise of this technology.
William A. Hartman, Chairman, President & CEO of Halberd Corporation said that the company’s patented extracorporeal treatment process enables it to treat particular diseases outside of the body.
Hartman added that the approach lowers or eliminates potential side-effects from standard treatments like drugs injected into a body or administered orally.
The filing is its tenth provisional patent application in less than a year and every patent demonstrates the incremental success of the company’s exclusive strategy.
The CEO further said that the company has experienced encouraging results to date for the successful eradication of Alzheimer’s Disease antigens.